Get started
Author

Paola Mariglia

Observed name: P. Mariglia
Observed institution: Sapienza University of Rome
OpenAlex ID: A5085793572
Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia
2016 · Marilisa Marinelli, Caterina Ilari, et al. · Oncotarget · 49
PDF
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
2021 · Maria Cristina Puzzolo, Ilaria Del Giudice, et al. · Frontiers in Oncology · 33
PDF
A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.
2015 · Giovanni F Torelli, Carmela Rozera, et al. · PubMed Central · 33
Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab
2021 · Maria Cristina Puzzolo, Giulia Radice, et al. · Blood · 27
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations
2020 · Sara Raponi, Caterina Ilari, et al. · British Journal of Haematology · 23
PDF
Genetic landscape of ultra-stable chronic lymphocytic leukemia patients
2018 · S. Raponi, I. Del Giudice, et al. · Annals of Oncology · 19
PDF
Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients
2014 · Nadia Peragine, Giovanni F. Torelli, et al. · Cancer Immunology Immunotherapy · 17
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study
2021 · Gian Matteo Rigolin, Ilaria Del Giudice, et al. · Blood · 16
PDF
Biallelic BIRC 3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease
2018 · Sara Raponi, Ilaria Del Giudice, et al. · British Journal of Haematology · 13
PDF
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation
2022 · Maria Cristina Puzzolo, Massimo Breccia, et al. · Journal of Clinical Medicine · 10
PDF
Unravelling the suboptimal response of TP 53‐mutated chronic lymphocytic leukaemia to ibrutinib
2018 · Anna Guarini, Nadia Peragine, et al. · British Journal of Haematology · 10
PDF
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
2021 · Luciana Cafforio, Sara Raponi, et al. · Haematologica · 9
PDF
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab
2020 · Nadia Peragine, Maria Stefania De Propris, et al. · Haematologica · 8
PDF
ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia
2020 · Maria Stefania De Propris, Stefania Intoppa, et al. · British Journal of Haematology · 8
The Antileukemic Potential of Natural Killer Cells
2016 · Giovanni F Torelli, Nadia Peragine, et al. · Immunotherapy · 2
TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment
2018 · Ilaria Del Giudice, Luciana Cafforio, et al. · Blood · 1
Pf365 Prognostic Implications of Ighv Gene Rearrangements With “borderline” Percentage of Mutations in Chronic Lymphocytic Leukemia Patients
2019 · S. Raponi, C. Ilari, et al. · HemaSphere
Pf359 Tp53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment
2019 · L. Cafforio, L.V. Cappelli, et al. · HemaSphere
Spontaneous Clinical Regression In Chronic Lymphocytic Leukemia : Clinical And Biologic Features Of 9 Cases From The ERIC Registry
2017 · Ilaria Del Giudice, Andrea Visentin, et al. · Haematologica
Expanded Natural Killer Cells For The Control Of Minimal Residual Disease In Ph+ Acute Lymphoblastic Leukemia Patients
2013 · Giovanni Fernando Torelli, Nadia Peragine, et al. · Blood
Works count: 25
Citation count: 278
H-index: 10
I10-index: 11
Year
Topic
Type